Teleflex (NYSE:TFX – Free Report) had its price target raised by Truist Financial from $210.00 to $221.00 in a research note issued to investors on Monday morning, Benzinga reports. The firm currently has a hold rating on the medical technology company’s stock.
Several other research firms have also recently issued reports on TFX. StockNews.com initiated coverage on Teleflex in a report on Thursday, October 5th. They issued a hold rating on the stock. Stephens reiterated an overweight rating and issued a $275.00 price target on shares of Teleflex in a report on Friday. JMP Securities decreased their price target on Teleflex from $315.00 to $285.00 and set a market outperform rating on the stock in a report on Friday. Royal Bank of Canada raised their price target on Teleflex from $218.00 to $228.00 and gave the company an outperform rating in a report on Friday. Finally, Morgan Stanley reiterated an equal weight rating and issued a $261.00 price target on shares of Teleflex in a report on Wednesday, July 19th. Six investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, the stock has an average rating of Hold and a consensus target price of $258.40.
Teleflex Price Performance
Teleflex Announces Dividend
The firm also recently declared a quarterly dividend, which will be paid on Friday, December 15th. Stockholders of record on Wednesday, November 15th will be given a dividend of $0.34 per share. This represents a $1.36 dividend on an annualized basis and a dividend yield of 0.64%. The ex-dividend date of this dividend is Tuesday, November 14th. Teleflex’s dividend payout ratio is currently 15.94%.
Institutional Investors Weigh In On Teleflex
Hedge funds have recently modified their holdings of the business. Kentucky Retirement Systems Insurance Trust Fund acquired a new stake in shares of Teleflex during the first quarter worth about $423,000. Mirova acquired a new stake in Teleflex in the 1st quarter valued at approximately $101,000. Raymond James Trust N.A. raised its position in Teleflex by 6.0% in the 1st quarter. Raymond James Trust N.A. now owns 2,155 shares of the medical technology company’s stock valued at $546,000 after buying an additional 122 shares during the last quarter. US Bancorp DE raised its position in Teleflex by 3.7% in the 1st quarter. US Bancorp DE now owns 9,116 shares of the medical technology company’s stock valued at $2,309,000 after buying an additional 322 shares during the last quarter. Finally, Symmetry Partners LLC acquired a new stake in Teleflex in the 2nd quarter valued at approximately $204,000. Institutional investors and hedge funds own 97.15% of the company’s stock.
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.
- Five stocks we like better than Teleflex
- What is the Australian Securities Exchange (ASX)
- These 5 small-cap impact stocks are making social change
- There Are Different Types of Stock To Invest In
- Alphabet slays its earnings but falls on its sword with cloud
- How to Start Investing in Penny Stocks
- There’s nothing artificial about NVIDIA’s relationship with AI
Receive News & Ratings for Teleflex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex and related companies with MarketBeat.com's FREE daily email newsletter.